This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Asparaginase
Description: Elspar contains the enzyme L-asparagine amidohydrolase, type EC-2, derivedfrom Escherichia coli. In a significant number of patients with acute leukemia, particularly lymphocytic, the malignant cellsare dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase.
The use of this drug has decreased since the approval of a pegylated version, Oncospar, with a longer serum half-life.
Elspar was originally developed by Merck.
Merck and Lundbeck
In 2006, Lundbeck acquired the rights to Elspar from Merck.
Lundbeck and Recordati
In December 2012, Lundbeck announced that the company has entered into an asset purchase agreement with Recordati that will acquire a portfolio of Lundbeck's non-core products primarily related to the United States. As part of this transaction, Recordati has acquired rights to the following products: Chemet (succimer), Cosmegen (dactinomycin for injection), Desoxyn (methamphetamine hydrochloride), Elspar (asparaginase), Indocin (indomethacin), Mustargen (mechlorethamine HCL for injection), NeoProfen (ibuprofen lysine), Panhematin (hemin), Peganone (ethotoin) and Tranxene (clorazepate).
Under the terms of the agreement, Recordati has acquired and retains all of Lundbeck's rights and responsibilities for the manufacturing, distribution and sale of the products. The transaction is expected to close at...See full deal structure in Biomedtracker
Pink Sheet Enzon's PEG-L-asparaginase
Additional information available to subscribers only: